Highlights

  • CONNEQT Health (ASX:CQT) reported FY2026 Revenue of A$6.3 million, up 77% year on year.
  • Consumer revenue contributed around A$4.0 million, while research revenue was approximately A$2.3 million.
  • Recurring revenue indicators improved, but they remain small relative to the company’s broader cost base.
  • Cash, debt, Negative equity and future funding requirements remain key areas to monitor.

CONNEQT Health (ASX:CQT) finished FY2026 with a materially stronger revenue profile, supported by consumer sales and research-related income. However, the company’s financial position remains a central part of the Investment case, with a relatively modest cash balance, ongoing operating outflows and negative Shareholder equity.

The result shows progress in commercial execution, but the next stage will depend on whether higher revenue can translate into stronger cash generation and a more sustainable funding position.

From AtCor to CONNEQT

CONNEQT Health (ASX:CQT) has operated under several corporate identities since listing on the ASX in 2005.

The Business was previously known as AtCor Medical and later CardieX before adopting the CONNEQT Health name in 2025.

Its core technology platform is built around SphygmoCor, which is used to assess central blood pressure and arterial function in clinical and research settings.

The consumer-facing extension of that technology is CONNEQT Pulse, an FDA-cleared home arterial health monitor.

The company’s broader strategy is to build a connected health platform around devices, clinical software, data and recurring digital services.

What the FY2026 numbers show

CONNEQT Health (ASX:CQT) reported total FY2026 revenue of approximately A$6.3 million, representing growth of 77% year on year.

Revenue was split between roughly A$4.0 million from the consumer business and around A$2.3 million from research activities.

The June quarter delivered record consumer revenue of approximately A$1.3 million, while cumulative CONNEQT Pulse units reached 3,574.

Currency exposure is also relevant because the company reports in Australian dollars while a meaningful part of its revenue and expenditure is linked to the United States.

That creates potential foreign-exchange effects when comparing reported periods.

Recurring revenue is building

CONNEQT is also attempting to increase the proportion of Recurring Revenue generated through enterprise and software-based products.

Contracted enterprise annualised recurring revenue reached approximately A$94,200, representing growth of 70%.

Cumulative contracted value stood at around A$163,800.

In-app purchases increased from about A$40,000 to A$68,000, while clinical subscription sites expanded from two to 17.

These figures show progress, but they remain small in absolute terms compared with the company’s operating cost base.

Management has also indicated that annualised underlying operating costs were reduced by approximately 30% to a range of A$10 million to A$12 million, excluding cost of goods and marketing.

The commercial challenge is therefore not simply to grow recurring revenue, but to do so quickly enough to narrow the gap between income and expenditure.

A narrowing loss is not a profit

CONNEQT Health (ASX:CQT) remained loss-making in FY2026.

Available reporting indicates a statutory loss of approximately A$10.9 million, compared with a larger loss in the prior year.

However, the more important issue is the balance sheet.

Cash stood at approximately A$2.57 million at 30 June 2026, while total Debt was around A$3.53 million.

Shareholder equity was negative at roughly A$228,000.

Free cash outflow was also substantial over the year.

These figures underline the importance of Liquidity management even as revenue growth improves.

A company can grow its Top Line while still remaining dependent on external funding if operating cash outflows remain elevated.

Capital support remains important

CONNEQT completed a A$5.5 million Placement in June 2026 and also launched a share purchase plan.

The company has further noted continued financial support from shareholder C2 Ventures.

These funding initiatives provide additional liquidity, but they also highlight the broader issue of Capital dependency.

Repeated equity issuance can dilute existing shareholders, particularly when the business has not yet reached cash-flow breakeven.

For CONNEQT Health (ASX:CQT), the balance between funding growth and controlling dilution will remain important as management continues to expand consumer and enterprise channels.

New channels add opportunity

In early September 2026, CONNEQT Health announced a Marketing agreement with Blueprint, the US longevity platform founded by Bryan Johnson.

Under the arrangement, CONNEQT Pulse is being made available through the Blueprint marketplace with referral links.

No financial terms were disclosed.

That means the agreement should be viewed as a distribution and customer-acquisition initiative rather than a quantified revenue event.

The commercial significance will depend on whether the channel generates sustained unit sales and repeatable revenue.

The company is also progressing regulatory work around SphygmoCor Cloud, including an FDA pre-submission lodged in June 2026.

This adds another potential growth avenue, although regulatory progress and eventual commercialisation remain separate steps.

Risks and outstanding questions

Funding remains the most immediate risk.

The company’s cash position is modest relative to historical cash outflows, while negative equity indicates limited balance-sheet flexibility.

That makes the outcome of the share purchase plan and any subsequent capital raising particularly relevant.

The company also needs to demonstrate that enterprise recurring revenue can scale meaningfully beyond its current base.

Consumer revenue growth is encouraging, but a durable path to breakeven will likely require a combination of higher device sales, growing subscriptions, better Operating Leverage and continued cost discipline.

What to watch

The first area to monitor is the full Annual Report and any further detail around liquidity, Going Concern and cash requirements.

The second is the outcome of the share purchase plan and whether additional funding is required.

The third is consumer momentum, particularly whether CONNEQT Pulse sales continue to build through new distribution relationships.

The fourth is recurring revenue growth from enterprise and clinical software offerings.

For CONNEQT Health (ASX:CQT), FY2026 showed clear progress on revenue, but the Balance Sheet remains the main constraint. The next phase will depend on whether stronger commercial activity can translate into improved Cash Flow before further capital becomes necessary.